Please find attached transcript of the Investor Conference call for Q1FY27 held on July 30, 2026

August 4, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Investor Conference Call for Q1FY27 – Transcript Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Pursuant to Regulation 30 of the Listing Regulations, please find enclosed herewith the transcript of the Investor Conference Call for Q1FY27 held on Thursday, July 30, 2026 at 06:30 P.M. (IST). The transcript is also available on the website of the Company at www.mankindpharma.com. You are requested to kindly take the same on records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a “Mankind Pharma Limited Q1 FY27 Earnings Conference Call” July 30, 2026 MANAGEMENT: MR. RAJEEV JUNEJA – VICE CHAIRMAN AND MANAGING DIRECTOR MR. SHEETAL ARORA – CHIEF EXECUTIVE OFFICER AND WHOLE-TIME DIRECTOR MR. SUDIPTA ROY – SENIOR PRESIDENT, SALES AND MARKETING MR. ASHUTOSH DHAWAN – GLOBAL CHIEF FINANCIAL OFFICER MR. PRAKASH AGARWAL – PRESIDENT STRATEGY MR. ARCHIT GUPTA – MANAGER IR Page 1 of 18 Mankind Pharma Limited July 30, 2026 Moderator: Good day, and welcome to Mankind Pharma Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Please note that this meeting is being recorded. I'll now hand the conference over to Mr. Archit Gupta from Mankind Pharma Limited. Thank you, and over to you, sir. Archit Gupta: Thank you, Yashashri. Good evening, everyone, and thank you for joining us for our first quarter FY27 Earnings Conference Call. On the call today, we have Mr. Rajeev Juneja, our Vice Chairman and Managing Director; Mr. Sheetal Arora, Chief Executive Officer and Whole-Time Director; Mr. Sudipta Roy, Senior President, Sales and Marketing; Mr. Ashutosh Dhawan, Global Chief Financial Officer; and Mr. Prakash Agarwal, President, Strategy. We will commence today's call with opening remarks from Mr. Rajeev Juneja, who will provide an overview of the quarter, followed by key business updates from Mr. Sheetal Arora. Mr. Ashutosh Dhawan will then share the detailed financial performance for the quarter, following which we will open the floor for the Q&A session. Before we begin, please note that today's discussion may include certain forward-looking statements based on management's current expectations. These statements are subject to various risks and uncertainties that may cause actual results to differ materially, and Mankind does not undertake any obligation to update or revise these statements in the future. Please refer to the detailed disclaimer available in the investor presentation uploaded on our website. With that, I now hand over the call to Rajeev sir, for his remarks. Rajeev Juneja: Thank you, Archit, and a very good evening to all. Welcome to Quarter 1 FY27 Earnings Call. Our disciplined execution and strengthening business fundamentals resulted in improvements across key operating and financial metrics in quarter 1 FY27, laying the foundation to deliver a sustainable growth. During the quarter, overall revenue increased to INR4,031 crores, up 13% year-on-year with EBITDA of INR1,060 crores and EBITDA margin improving by 250 bps year-on-year to 26.3%. Revenue from the domestic business, excluding Consumer Healthcare, increased by 11% year- on-year to INR3,180 crores quarter 1 FY27, led by double-digit growth in base business and a strong growth momentum in chronic and BSV specialty business. The secondary sales as per IQVIA grew 12.7% during the quarter, led by healthy volume growth of 4.7%, which increased by 220 bps year-on-year. Growth was supported by continued strong momentum in chronic portfolio and outperformance in the gastro, vitamins and gynaec segments, which led to growth recovery in acute business. In recent years, IPM has witnessed a significant shift towards chronic and specialized therapies, driven largely by the rising prevalence of chronic diseases and changing lifestyle. In line with this trend, we are steadily expanding our presence in chronic and specialty therapies while continuing to strengthen our own multi-specialty business. I'm delighted to share that our Page 2 of 18 Mankind Pharma Limited July 30, 2026 focused initiatives across key chronic therapies have translated into increase of 80 bps year-on- year in our chronic share, excluding BSV, to 40%, primarily driven by strong growth of 19.4% in cardiac, 12.7% in anti-diabetic. We remain focused on increasing our chronic share to 50% in medium term. To further strengthen our presence in multi-specialty business, we have launched a new division, Vistar, which would help scale some of the lesser focused brands in existing divisions. Moving ahead, our Consumer Healthcare business delivered a revenue of INR246 crores in quarter 1 '27, partly impacted by discounted cash and carry business. Despite softer growth, we gained market share in key brands Manforce, Preganews, Gas-o-fast. also, our modern trade and e-commerce share increased to 15% from 11% a year ago, supported by 38% growth in that channel. Innovation and specialization continue to remain central to our long-term strategy, and we are steadily building differentiated science-led pipeline that complement our existing portfolio. We've also partnered with Denovo Science to launch an AI-led drug discovery program, marking an important step in strengthening our innovation-driven and technology-enabled R&D capabilities. We remain committed to deliver innovative science-backed products at affordable prices, ensuring access across the country and driving sustainable long-term growth. I will now invite Sheetal to walk you through more details on our business performance. Sheetal Arora: Good evening, everyone, and thank you for joining us for Mankind Pharma's Quarter 1 Financial Year 2027 Earnings Call. It's a pleasure to connect with all of you today. Financial year 2027 started with a healthy growth rate carrying forward the momentum from the last few quarters as we continue to witness sequential improvement across our businesses. Let me begin with our overall domestic business. In Quarter 1 Financial Year 2027, revenue from our domestic business increased by 10.5% year-on-year to INR3,426 crores. This growth was driven by a 15.8% increase in our chronic portfolio, growth recovery in the acute portfolio, and strong double-digit growth in BSV. Let me share some key highlights for the quarter, starting with our chronic business, an important long-term growth driver for us. In anti-diabetes, excluding tirzepatide, we outperformed IPM by 1.1x. The Glizid brand family continues to demonstrate strong momentum, delivering 29% year- on-year growth in Quarter 1 Financial Year 2027. In Cardiac, we outperformed IPM by 1.1x, growing 19.4% year-on-year. Our Telmikind family grew approximately 21% year-on-year, while Lipirose and Statpure grew 30% and 31% respectively. Coming to Acute therapies, our Acute portfolio has steadily recovered and is now broadly in line with IPM growth, improving from 6.1% in quarter 1 Financial Year 2026 to 10.9% in quarter 1 Financial Year 2027. Page 3 of 18 Mankind Pharma Limited July 30, 2026 Our gastro portfolio outperformed the market by 1.2x of IPM, growing at 13.6% year-on-year with 1.8x outperformance in Pantakind. In gynaecology, we delivered 12.7% year-on-year growth ahead of IPM growth of 12.1%, primarily led by continued strong double-digit growth in our IVF portfolio, up 39% in both Foligraf and Humog, and 20% growth in Dydroboon, that is 1.5x of market growth. We continue to see healthy momentum in VMN growing 19.3% year-on-year, [Showing first 8,000 characters — download PDF for full document]